A randomised, double-blind, placebo-controlled Phase II study to target the type I IFN receptor by administrating Anifrolumab in RA patients with a high IFN signature (TarIFNiRA)
Phase of Trial: Phase II
Latest Information Update: 13 Dec 2018
Price : $35 *
At a glance
- Drugs Anifrolumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms TarIFNiRA
- 22 May 2018 Status changed from not yet recruiting to recruiting.
- 27 Mar 2018 Planned initiation date changed from 20 Feb 2018 to 20 Apr 2018.
- 28 Dec 2017 New trial record